Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Abstract

Purpose: To identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the first-inclass, oral CDK4/6 inhibitor PD 0332991 administered once daily for 21 of 28 days (3/1 schedule) in patients with retinoblastoma protein (Rb)-positive advanced solid tumors and to describe pharmacokinetic-pharmacodynamic relationships relative to drug effects.Experimental Design: This open-label phase I study (NCT00141297) enrolled patients who received PD 0332991 orally in six dose-escalation cohorts in a standard 3 þ 3 design.Results: Forty-one patients were enrolled. DLTs were observed in five patients (12%) overall; at the 75, 125, and 150 mg once daily dose levels. The MTD and recommended phase II dose of PD 0332991 was 125 mg once daily. Neutropenia was the only dose-limiting effect. After cycle 1, grade 3 neutropenia, anemia, and leukopenia occurred in five (12%), three (7%), and one (2%) patient(s), respectively. The most common non-hematologic adverse events included fatigue, nausea, and diarrhea. Thirty-seven patients were evaluable for tumor response; 10 (27%) had stable disease for !4 cycles of whom six derived prolonged benefit (!10 cycles). PD 0332991 was slowly absorbed (median T max , 5.5 hours), and slowly eliminated (mean half-life was 25.9 hours) with a large volume of distribution (mean, 2,793 L). The area under the concentration-time curve increased linearly with dose. Using an E max model, neutropenia was shown to be proportional to exposure.Conclusions: PD 0332991 warrants phase II testing at 125 mg once daily, at which dose neutropenia was the sole significant toxicity. Clin Cancer Res; 18(2); 568-76. Ó2011 AACR.

Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options

“…CDK4 amplification has been reported 42 in 1.5% to 15% of breast carcinomas and expression has been correlated with amplification. Recent results [43][44][45][46] focused on targeting cell-cycle regulatory genes in clinical trials for patients with cancer, and alterations in those cell growth regulatory pathways are showing significant promise.…”

RB1: a prototype tumor suppressor and an enigma

“…In contexts where deregulation of Cyclin D:Cdk4/6 kinases drives tumorigenesis, inhibition of these kinases can trigger cellular senescence or apoptosis (Fry et al 2004;Thangavel et al 2011;Choi et al 2012;Sawai et al 2012). Cdk4/6 inhibitors had modest effects when tested as a monotherapy in solid tumors (Flaherty et al 2012;Dickson et al 2013;Cadoo et al 2014;DeMichele et al 2015;Vaughn et al 2015). This may reflect the fact that many signaling pathways converge on CDK regulation, and cells can express alternative CDKs that phosphorylate similar or overlapping sets of substrates.…”

Resistant mechanisms to BRAF inhibitors in melanoma

“…Cyclin D1 amplifications are found in about 20% of BRAF mutated melanomas. CDK4-6 inhibitors (key regulators of G1-S transition of the cell cycle) alone failed to decrease tumor size, but when BRAF and MEK inhibitors were combined, complete responses were achieved in 30% of mouse models (22).…”